Click me
Transcribed

xarelto-lawyer-rivaroxaban-side-effects-infographic

Xarelto (Rivaroxaban) is an anticoagulant drug and the first direct Xa inhibitor taken orally. Doctors have found the drug to be predictable and require less monitoring. However, the anticoagulant effect of Xarelto, unlike other anticoagulants, does not have an antidote in the event of excessive bleeding. In July 2011, the FDA approved Xarelto for sale on the market by Janssen Pharmaceuticals. The drug is used to treat blood clots but a recent report found that blood clots "were the predominant serious adverse events reported, accounting for 158 cases." In July 2011, the FDA approved Xarelto for sale on the market by Janssen Pharmaceuticals. In September, The New England Journal of Medicine published a study that found Xarelto did not provide any bleeding-prevention benefit over the traditional treatment, Warfarin, in patients suffering from atrial fibrillation. APPROVED COMMON SIDE EFFECTS: Headache In June 2012, an FDA advisory panel voted against approving Xarelto for the treatment of acute coronary syndrome. The primary concern raised by the panel was the fact that 15% of study participants dropped out of the Phase 3 study. In October, the Institute for Safe Medication Practices (ISMP) issued its QuarterWatch report based on FDA data from the first quarter of 2012. During this period, the FDA 356 adverse event reports of "serious, disabling, or fatal injury" on Xarelto. Additionally, 158 reports indicated blood clots were the serious side effect. By October, the FDA had received 2,754 adverse event reports concerning Xarelto. Among these were 386 cases of pulmonary embolism, 279 cases of deep vein thrombosis, and 107 cases of gastrointestinal hemorrhage. Swelling Unusual Bruising or Bleeding SERIOUS SIDE EFFECTS: Blood Clots Gastrointestinal Hemorrhage Serious, Disabling or Fatal Reports 356 Reported Blood Clots 158 Adverse Reports Spinal hemorrhage: The FDA has included a black box warning stating that spinal hemorrhages have occurred and may result in long-term 2,754 or permanent paralysis. Pulmonary Embolism 386 Intracranial Hemorrhage Deep Vein Thrombosis Epidural Hemorrhage Cerebral Hemorrhage 279 Gastrointestinal Hemorrhage Stroke 107 In February 2013, the New England Journal of Medicine published the results of the MAGELLAN study, which found the Xarelto helps prevent bloods clots but may carry an increased risk of bleeding. Blood Clot Increased Risk of BLEEDING Call the law offices of d'Oliveira & Associates at 1-800-992-6878 Xarelto

xarelto-lawyer-rivaroxaban-side-effects-infographic

shared by dmlaw on Apr 01
321 views
0 shares
0 comments
The anticoagulant blood-thinning drug Xarelto, which is manufactured by Bayer AG and is marketed in the United States by the Johnson & Johnson subsidiary Janssen Pharmaceutical, was approved by The U....

Tags

None.

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size